280 results about "Control release" patented technology

The invention belongs to the technical field of gel dressings, and particularly relates to a bio-based gel dressing for wound treatment and a preparation method thereof.The bio-based gel dressing is prepared from, by weight, 10-17 parts of mussel mucin, 13-20 parts of silk fibroin, 1-5 parts of plant vesicles, 2-4 parts of traditional Chinese medicine polysaccharide, 0.05 part of antibacterial peptide, 1.5 parts of glycerinum and 0.3 part of cross-linking agent; nano plant vesicles which are extracted from a traditional Chinese medicine prescription and have the effect of promoting wound healing are used as a carrier for encapsulating antibacterial peptide, and then the antibacterial peptide is encapsulated in a three-dimensional gel network formed by natural protein, so that controlled release and slow release of antibacterial and anti-inflammatory components are realized, and efficient wound healing is promoted.

The invention discloses an embolism microsphere and a preparation method thereof.The embolism microsphere is prepared through the following steps that a polycarboxylate microsphere is prepared by combining a free radical polymerization method and an emulsion polymerization method, and the polycarboxylate microsphere is obtained; and saponifying and hydrolyzing the polycarboxylate microspheres to hydrolyze the polycarboxylate microspheres to obtain hydroxyl polymer microspheres, and introducing an acidic group onto the hydroxyl polymer microspheres to obtain the embolism microspheres containing both the hydroxyl group and the acidic group. The embolism microsphere disclosed by the invention realizes high loading capacity and controllable release of the anti-tumor drug, realizes accurate embolism in blood flow, and improves the treatment effect of the drug.

The invention discloses a photocuring microneedle with ginseng exosome loaded berberine, a preparation method of the photocuring microneedle and application of the photocuring microneedle to tissue repair. A ginseng exosome loaded berberine compound is prepared through a microfluidic technology; filling a needle cavity of a microneedle mold with a needle tip layer preparation solution containing the compound, methylacryloylated hyaluronic acid and methylacryloylated gelatin through a centrifugal method; covering a backing layer preparation solution composed of hyaluronic acid and povidone K90, and centrifuging again; and finally, carrying out light curing, drying and demolding. The prepared composite microneedle is complete and sharp in needle shape and high in forming rate; the efficient entrapment of the active medicine is realized; the biocompatibility is good, and the irritation is low; a cross-linked network structure formed by photocuring is beneficial to realizing controlled release of drugs, the targeted repair function of the ginseng exosome is combined with the hypoglycemic effect of berberine, and a new strategy and technical approach with a prospect are provided for painless, efficient and long-acting treatment of diabetes mellitus.

It relates to drug delivery systems and methods for locally delivering therapeutic agents, and methods for using such drug delivery systems for the treatment of diseases.

The invention relates to the technical field of drug-loaded microparticles, in particular to a preparation method and application of medical stone / PLGA composite drug-loaded microparticles, medical stone and PLGA are prepared into a structure with activated nano medical stone as a core and a PLGA polymer as a shell through the processes of ball milling, acid activation, emulsification, solvent volatilization and the like, and the medical stone and the PLGA are synergistically matched, so that the drug-loaded microparticles have the advantages that the drug-loaded microparticles are uniform in particle size distribution, and the drug-loaded microparticles have good drug-loaded performance. Firstly, the hydrogel has intelligent responsiveness, can accelerate degradation in alkaline and enzyme environments of wound surfaces, and realizes accurate release of drugs as required; secondly, the long-acting controlled release property is shown, and a dual sustained release barrier is constructed through medical stone adsorption and PLGA wrapping, so that the medicine is released for more than 72 hours at a constant speed following zero-order dynamics, and burst release is effectively avoided. And thirdly, when the drug-loaded particles are used for hydrogel, the drug-loaded particles in nanoscale are combined with the hydration effect of a hydrogel matrix, so that the efficient permeability of the drug in the cuticle is greatly improved.

The invention provides a seawater soaking wound hydrogel dressing and a preparation method thereof, a drug-loaded nano system 4OI (at) ZIF-8 (at) PAD with a core-shell structure is constructed, an anti-inflammatory drug 4-octyl itaconic acid and zinc ions are jointly encapsulated in a ZIF-8 framework, and a polydopamine coating is wrapped, so that synergistic loading and controllable release of the drug and metal ions are realized. According to the dressing, dopamine modified hyaluronic acid is used as a matrix, a temperature-sensitive material and an enzyme catalysis cross-linking system are combined, stable gel can be rapidly formed in situ within 5 seconds, and the dressing has excellent tissue adhesion performance (the adhesion strength reaches 6.7 kPa). Experiments prove that the hydrogel dressing has the characteristics of broad-spectrum antibiosis, inflammation regulation and control and long-acting release. Animal experiments prove that the healing rate of seawater soaking wounds treated by the dressing on the twelfth day is as high as 95.7% and is remarkably superior to that of a commercial silver ion gel control group, scars are less after healing, and an efficient, safe and easy-to-implement scheme is provided for marine environment wound nursing.

The invention relates to the technical field of fibers, in particular to a controlled-release anti-aging polypropylene fiber and a preparation method thereof. The fiber is prepared from polypropylene homopolymer resin, a reaction type interface layer master batch and a controlled release anti-aging master batch, the reactive interface layer master batch is formed by reacting and extruding maleic anhydride modified polypropylene and 3-aminopropyl terminated polydimethylsiloxane, so that the interface compatibility is enhanced; the controlled-release anti-aging master batch contains hydroxyl and peracetylated cyclodextrin grafted siloxane carriers, and an ultraviolet absorbent, a light stabilizer and an antioxidant are included, so that the controlled release of an anti-aging agent is realized. The preparation method comprises the steps of master batch preparation, final mixing granulation, melt spinning and drafting setting. The fiber strength is remarkably improved, the boiling water shrinkage rate is reduced, the strength retention rate after ultraviolet aging reaches 93% or above, the yellow index change is small, and the outdoor service life is prolonged.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

An oral product includes a filler and an active ingredient. The filler includes a modified agglomerate and a surface modifier. The modified agglomerate includes a porous carrier. The surface modifier coats at least a portion of a surface of the agglomerate, is in pores of the agglomerate, or both coats at least a portion of the surface of the agglomerate and is in pores of the agglomerate. The surface modifier includes a sugar alcohol or a hydrophobic material. The active ingredient is admixed with the filler.

The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and / or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.

This invention discloses a controlled-release solid film formulation for pesticides, its preparation method, and its applications. This invention upgrades pesticides from liquid / powder formulations to solid film formulations, utilizing the solid film to physically block pesticide drift, diffusion, and loss, reducing off-target effects at the source. Through the combined use of physical and chemical techniques, pesticides are uniformly distributed within the solid film, and the pesticide release cycle is synchronized with the solid film degradation, achieving precise controlled release. This solid film formulation is applied from the beginning of crop growth, synchronized with the plant growth cycle, providing early preventative effects through quantitative controlled release of pesticides. This solid film formulation also functions as a mulch film; its preparation process is simple and easy, it is completely degradable and requires no recycling, reducing costs. The identification method of this invention utilizes selective precipitation separation technology, achieving high pesticide extraction efficiency of 95%-98%, especially suitable for low water-soluble pesticides. The drug identification process is simple to operate: the entire process takes less than 4 hours, requires no complex purification steps, and is suitable for batch sample processing.

The invention provides a mesenchymal stem cell composition as well as a preparation method and application thereof in knee joint products, and belongs to the technical field of medicines. The invention relates to application of a mesenchymal stem cell combined naringin derivative in preparation of medicines for treating osteoporosis and repairing knee joint injury and arthritis. The naringin derivative is prepared from naringin through an ether esterification reaction, the metabolic cycle of the naringin derivative is prolonged and the water solubility is improved while the original activity is maintained, so that the free drug concentration and tissue infiltration capacity in bones are improved, the bioavailability of the naringin derivative is improved, and the bioavailability of the naringin derivative is improved. The prepared mesenchymal stem cell composition can induce mesenchymal stem cell osteogenic differentiation and improve bone repair capacity, has a good intervention effect on osteoporosis, has a sustained and controlled release effect and prolongs medicinal time.

The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.

This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.

To provide a polyherb gel delivery device that maintains the stability and antioxidant activity of herbal ingredients, ensuring a long shelf life, controlled release of active ingredients, ease of use, and suitability for large-scale dietary supplement and functional food applications. The polyherb gel delivery device (100) comprises a gel matrix (102), an antioxidant barrier layer (104), and an outer container (106). The gel matrix (102) is centrally located and surrounded by the barrier layer (104), which is further surrounded by the outer container (106), forming an integrally connected multi-layer structure suitable for stably encapsulating the herb gel composition.

The invention relates to a nicotine bagged filling agent. The nicotine bagged filling agent comprises nicotine; a controlled release excipient comprising one or more selected from the group consisting of cellulose and sugar alcohols; a binder; a pH adjusting agent; and a perfume. Wherein the content of the nicotine is 2.5 wt% to 10 wt% of the weight of the total solid contents of the bagged filler for the nicotine, and the content of the controlled release excipient is 5.5 times to 36 times of the content of the nicotine.

The invention provides a controlled release method of a low-additive-amount coal-based quantum carbon dot composite coated slow-release fertilizer, and relates to the technical field of slow-release fertilizers, the controlled release method comprises the following steps: S1, carrying out surface functional modification on coal-based quantum carbon dots, grafting amino and carboxyl on the surfaces of the coal-based quantum carbon dots, and forming molecular-level crosslinking points capable of being subjected to dual crosslinking with inorganic silicon-oxygen bonds and organic ester bonds; s2, sequentially wrapping a basic controlled release shell layer formed by biodegradable polyester and an intelligent response layer embedded with the coal-based quantum carbon dots by taking fertilizer particles as a core through a layer-by-layer spraying and fluidized bed coating process to form a composite coating structure; the coal-based quantum carbon dots subjected to surface functionalization modification serve as molecular-level crosslinking points under the extremely-low addition amount of 0.1-1 wt%, the molecular-level crosslinking points, inorganic silicon-oxygen bonds and organic ester bonds form a double-crosslinking network, the compactness and stability of a coating layer are remarkably improved, and therefore the raw material cost and processing energy consumption are reduced, and green manufacturing is achieved.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

The embodiment of the application discloses a preparation method of a target temperature-sensitive drug-loaded composite microsphere based on attapulgite, which comprises the following steps: carrying out purification treatment on original attapulgite based on an aqueous solution of inorganic strong acid to obtain purified attapulgite; mixing the purified attapulgite, gypenoside, inulin and folic acid to obtain a mixture, and carrying out mixing treatment on the mixture based on deionized water to obtain a composite microsphere suspension; conveying the composite microsphere suspension into a spray dryer to carry out granulation to obtain primary drug-loaded composite microspheres; adopting a melt impregnation method to coat lauric acid on the surface and pores of the primary drug-loaded composite microspheres, and cooling the primary drug-loaded composite microspheres coated with lauric acid to room temperature to obtain the target temperature-sensitive drug-loaded composite microspheres. The application can not only realize temperature change-based on-off type control release of drugs, significantly improve the targeting and treatment accuracy of drugs, but also reduce the systemic toxic side effects of chemotherapy from the source, and realize efficient and low-toxicity synergistic treatment.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions for treatment of opioid dependence, pain or depression, including an aqueous suspension of crystalline 3-acyl-buprenoprhine, or a pharmaceutically acceptable salt thereof, wherein the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. This disclosure also includes 3-acyl-buprenoprhine or a pharmaceutically acceptable salt thereof prepared in a controlled release matrix, including poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein and a combination of two or more thereof.

The present application relates to the technical field of biological materials, in particular to a light-responsive drug gel carrier and a preparation method thereof, in order to improve the controlled release function of the hydrogel material, the methyl methacrylate nitrobenzene compound containing nitrobenzene structure, hydantoin structure and propylene structure is prepared first, under the action of a photoinitiator, the double bond is crosslinked with methyl methacrylate and ethylene glycol methacrylate to form a hydrophilic gel network, so that the drug gel carrier is obtained; wherein the nitrobenzene structure has photosensitivity, and the crosslinking structure will be broken under ultraviolet irradiation, thereby reducing the stability of the gel material, destroying the rearrangement of the gel micelle structure, and realizing the release of the loaded drug; and the hydantoin structure introduced in the methyl methacrylate nitrobenzene compound also has good antibacterial performance, which can effectively avoid wound infection and improve wound recovery.

The application discloses a kind of hierarchical response intelligent drug-loading units and its controlled-release system, including A type drug-loading microbubble and B type phase change droplet, A type drug-loading microbubble includes gas core and rigid shell, the first drug active substance is loaded in the rigid shell, and the A type drug-loading microbubble has first burst threshold;B type phase change droplet includes low-boiling liquid perfluorocarbon core and phospholipid shell, the second drug active substance is loaded in the phospholipid shell, and the B type phase change droplet has phase transition threshold and second burst threshold;Wherein, first burst threshold>Second burst threshold>Phase transition threshold.The application realizes the precision and intelligent controlled-release of drug, significantly improves curative effect and reduces toxic side effect, benefits from the core structure design of hierarchical response drug-loading unit and programmable ultrasonic excitation sequence, and the application completely changes the extensive release mode of traditional one-time blasting.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an anti-inflammatory analgesic indometacin long-acting suppository and a preparation method thereof.The suppository is composed of indometacin sustained-release microspheres and a modified fatty matrix; eudragit RS100 / RL100 is used as a compound framework of the sustained-release microspheres, the sustained-release microspheres are prepared through a spherocrystal granulation process, the modified fatty matrix is prepared from a mixed fatty glyceride compound matrix sustained-release aid, a three-dimensional suspending dispersant and the like through melting, pre-crystallization and high-speed homogenization processes, and the three-dimensional suspending dispersant contains modified nano silicon dioxide, glycerin monostearate and beewax. According to the invention, a microsphere-matrix dual controlled release system is constructed, so that burst release of drugs is eliminated, and long-acting stable release is realized; the microspheres are prevented from settling and agglomerating through a physical locking mechanism, and the storage stability of the preparation is improved by matching with a dual anti-oxidation system; meanwhile, rectal mucosa stimulation is reduced, the preparation process is simple, the quality is controllable, and the composition is suitable for anti-inflammation and analgesia of various diseases and has a wide clinical application prospect.

The invention discloses a colon-targeted pharmaceutical composition as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The invention aims to solve the technical problems that the existing 5-aminosalicylic acid preparation is low in targeted delivery efficiency and lacks a synergistic interaction mechanism. According to the pharmaceutical composition, 5-aminosalicylic acid is used as a treatment component, and pH response type composite hydrogel constructed by sodium humate and sodium alginate is used as a carrier. The core characteristic of the pH-responsive controlled-release hydrogel is that sodium humate is a functional carrier component for forming a hydrogel network and realizing pH-responsive controlled release, and meanwhile, sodium humate is also used as an active component and has a synergistic interaction effect with 5-aminosalicylic acid. By means of the intelligent carrier, release of the medicine in the stomach is effectively inhibited, effective enrichment and continuous medicine release at the colon part are achieved, the local medicine concentration is remarkably improved, and an efficient and safe new strategy is provided for treatment of ulcerative colitis.

The invention discloses a nano-drug formed by assembling triptolide and a TPA-(BT-TPE) 3 fluorescent probe with an AIE effect as well as a preparation method and application of the nano-drug. The two-photon triptolide nano-drug is a nano-particle and is formed by assembling triptolide and a TPA-(BT-TPE) 3 fluorescent probe through a drug solubilizing controlled release agent, the preparation method of the two-photon triptolide nano-drug comprises the following steps: a) dissolving raw materials: dissolving triptolide, a TPA-(BT-TPE) 3 fluorescent probe and a drug solubilizing controlled-release agent in an organic solvent together to form a premixed solution; b) nano precipitation: adding the premixed solution into a poor solvent of triptolide under a stirring condition, and stirring and evaporating until the organic solvent is completely removed to obtain a reaction mixture; and c) post-treatment: purifying and concentrating the reaction mixture to obtain a finished product. According to the invention, the treatment effect of the triptolide can be improved, and a visual basis can be provided for disease diagnosis and curative effect tracking by using a two-photon imaging technology.

The application discloses an STM2457-PLGA nano drug, an artificial lens and a preparation method and application thereof, and relates to the technical field of biological medicine. The preparation method of the STM2457-PLGA nano drug comprises the following steps: preparing nano microspheres by injecting an oil phase comprising STM2457 and PLGA and a water phase comprising PVA into a microfluidic chip, and obtaining the STM2457-PLGA nano drug after freeze-drying of the nano microspheres, wherein the particle size of the STM2457-PLGA nano drug is 50-300 nm. The long-acting release of STM2457 carried by the surface-modified artificial lens is realized through the controlled release effect of the PLGA nano microspheres, and the slow-release period can cover the high-incidence period of postoperative complications of cataract surgery through process optimization, far exceeding the traditional short-term release system, and can continuously meet the long-term prevention and treatment needs after surgery, and effectively reduce the risk of complications such as after-cataract.